Epigenetics-targeted drugs: current paradigms and future challenges
Open accessThe DOI matches its Crossref record; 1,077 of the 1,077 references it cites were found in a registry or an index.
Abstract
Epigenetics governs a chromatin state regulatory system through five key mechanisms: DNA modification, histone modification, RNA modification, chromatin remodeling, and non-coding RNA regulation. These mechanisms and their associated enzymes convey genetic information independently of DNA base sequences, playing essential roles in organismal development and homeostasis. Conversely, disruptions in epigenetic landscapes critically influence the pathogenesis of various human diseases. This understanding has laid a robust theoretical groundwork for developing drugs that target epigenetics-modifying enzymes in pathological conditions. Over the past two decades, a growing array of small molecule drugs targeting epigenetic enzymes such as DNA methyltransferase, histone deacetylase, isocitrate dehydrogenase, and enhancer of zeste homolog 2, have been thoroughly investigated and implemented as therapeutic options, particularly in oncology. Additionally, numerous epigenetics-targeted drugs are undergoing clinical trials, offering promising prospects for clinical benefits. This review delineates the roles of epigenetics in physiological and pathological contexts and underscores pioneering studies on the discovery and clinical implementation of epigenetics-targeted drugs. These include inhibitors, agonists, degraders, and multitarget agents, aiming to identify practical challenges and promising avenues for future research. Ultimately, this review aims to deepen the understanding of epigenetics-oriented therapeutic strategies and their further application in clinical settings.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Items 201–400 of 1,077
Molecular basis of histone H3K36me3 recognition by the PWWP domain of Brpf1
Vezzoli, A., Bonadies, N., Allen, M. D., Freund, S. M. V., Santiveri, C. M., Kvinlaug, B. T., Huntly, B. J. P., Göttgens, B., & Bycroft, M. (2010) · Nature Structural & Molecular Biology · doi:10.1038/nsmb.1797 · Cited by 218
Engstrom, L. D., Aranda, R., Waters, L., Moya, K., Bowcut, V., Vegar, L., Trinh, D., Hebbert, A., Smith, C. R., Kulyk, S., et al. (2023) · Cancer Discovery · doi:10.1158/2159-8290.cd-23-0669 · Cited by 217
Belinostat: First Global Approval
Poole, R. M. (2014) · Drugs · doi:10.1007/s40265-014-0275-8 · Cited by 216
Bromodomain and extraterminal (BET) proteins: biological functions, diseases and targeted therapy
Wang, Z.-Q., Zhang, Z.-C., Wu, Y.-Y., Pi, Y.-N., Lou, S.-H., Liu, T.-B., Lou, G., & Yang, C. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01647-6 · Cited by 216
Krug, L. M., Kindler, H. L., Calvert, H., Manegold, C., Tsao, A. S., Fennell, D., Öhman, R., Plummer, R., Eberhardt, W. E. E., Fukuoka, K., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)70056-2 · Cited by 215
Lai, C.-J., Bao, R., Tao, X., Wang, J., Atoyan, R., Qu, H., Wang, D.-G., Yin, L., Samson, M., Forrester, J., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-3360 · Cited by 212
Active turnover of DNA methylation during cell fate decisions
Parry, A., Rulands, S., & Reik, W. (2021) · Nature Reviews Genetics · doi:10.1038/s41576-020-00287-8 · Cited by 212
Tasselli, L., Xi, Y., Zheng, W., Tennen, R. I., Odrowaz, Z., Simeoni, F., Li, W., & Chua, K. F. (2016) · Nature Structural & Molecular Biology · doi:10.1038/nsmb.3202 · Cited by 211
Nuclear accumulation of HDAC4 in ATM deficiency promotes neurodegeneration in ataxia telangiectasia
Li, J., Chen, J., Ricupero, C. L., Hart, R. P., Schwartz, M. S., Kusnecov, A., & Herrup, K. (2012) · Nature Medicine · doi:10.1038/nm.2709 · Cited by 210
Kim, R. Y., Horvat, J. C., Pinkerton, J. W., Starkey, M. R., Essilfie, A. T., Mayall, J. R., Nair, P. M., Hansbro, N. G., Jones, B., Haw, T. J., et al. (2017) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2016.04.038 · Cited by 210
Garcia-Manero, G., Griffiths, E. A., Steensma, D. P., Roboz, G. J., Wells, R., McCloskey, J., Odenike, O., DeZern, A. E., Yee, K., Busque, L., et al. (2020) · Blood · doi:10.1182/blood.2019004143 · Cited by 210
Liu, H., Doke, T., Guo, D., Sheng, X., Ma, Z., Park, J., Vy, H. M. T., Nadkarni, G. N., Abedini, A., Miao, Z., et al. (2022) · Nature Genetics · doi:10.1038/s41588-022-01097-w · Cited by 209
Rajakumara, E., Wang, Z., Ma, H., Hu, L., Chen, H., Lin, Y., Guo, R., Wu, F., Li, H., Lan, F., et al. (2011) · Molecular Cell · doi:10.1016/j.molcel.2011.07.006 · Cited by 208
Self-citationRNA interference in the era of nucleic acid therapeutics
Jadhav, V., Vaishnaw, A., Fitzgerald, K., & Maier, M. A. (2024) · Nature Biotechnology · doi:10.1038/s41587-023-02105-y · Cited by 207
Chasing molecular glue degraders: screening approaches
Domostegui, A., Nieto-Barrado, L., Perez-Lopez, C., & Mayor-Ruiz, C. (2022) · Chemical Society Reviews · doi:10.1039/d2cs00197g · Cited by 200
Lee, J.-E., Park, Y.-K., Park, S., Jang, Y., Waring, N., Dey, A., Ozato, K., Lai, B., Peng, W., & Ge, K. (2017) · Nature Communications · doi:10.1038/s41467-017-02403-5 · Cited by 200
Clonal heterogeneity of acute myeloid leukemia treated with the IDH2 inhibitor enasidenib
Quek, L., David, M. D., Kennedy, A., Metzner, M., Amatangelo, M., Shih, A., Stoilova, B., Quivoron, C., Heiblig, M., Willekens, C., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0115-6 · Cited by 200
Li, H., Fischle, W., Wang, W., Duncan, E. M., Liang, L., Murakami-Ishibe, S., Allis, C. D., & Patel, D. J. (2007) · Molecular Cell · doi:10.1016/j.molcel.2007.10.023 · Cited by 199
Vitamin C in stem cell reprogramming and cancer
Cimmino, L., Neel, B. G., & Aifantis, I. (2018) · Trends in Cell Biology · doi:10.1016/j.tcb.2018.04.001 · Cited by 197
Safety and tolerability of histone deacetylase (HDAC) inhibitors in oncology
Shah, R. R. (2019) · Drug Safety · doi:10.1007/s40264-018-0773-9 · Cited by 197
Structural analysis of human KDM5B guides histone demethylase inhibitor development
Johansson, C., Velupillai, S., Tumber, A., Szykowska, A., Hookway, E. S., Nowak, R. P., Strain-Damerell, C., Gileadi, C., Philpott, M., Burgess-Brown, N., et al. (2016) · Nature Chemical Biology · doi:10.1038/nchembio.2087 · Cited by 197
DiNardo, C. D., Schuh, A. C., Stein, E. M., Montesinos, P., Wei, A. H., de Botton, S., Zeidan, A. M., Fathi, A. T., Kantarjian, H. M., Bennett, J. M., et al. (2021) · The Lancet Oncology · doi:10.1016/s1470-2045(21)00494-0 · Cited by 197
Bachy, E., Camus, V., Thieblemont, C., Sibon, D., Casasnovas, R.-O., Ysebaert, L., Damaj, G., Guidez, S., Pica, G. M., Kim, W. S., et al. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.21.01815 · Cited by 197
Mocetinostat for relapsed classical Hodgkin's lymphoma: an open-label, single-arm, phase 2 trial
Younes, A., Oki, Y., Bociek, R. G., Kuruvilla, J., Fanale, M., Neelapu, S., Copeland, A., Buglio, D., Galal, A., Besterman, J., et al. (2011) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70265-0 · Cited by 196
Witta, S. E., Jotte, R. M., Konduri, K., Neubauer, M. A., Spira, A. I., Ruxer, R. L., Varella-Garcia, M., Bunn, P. A., & Hirsch, F. R. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.38.9411 · Cited by 196
Fathi, A. T., DiNardo, C. D., Kline, I., Kenvin, L., Gupta, I., Attar, E. C., Stein, E. M., de Botton, S., & for the AG221-C-001 Study Investigators (2018) · JAMA Oncology · doi:10.1001/jamaoncol.2017.4695 · Cited by 195
The role of m6A methylation in therapy resistance in cancer
Zhuang, H., Yu, B., Tao, D., Xu, X., Xu, Y., Wang, J., Jiao, Y., & Wang, L. (2023) · Molecular Cancer · doi:10.1186/s12943-023-01782-2 · Cited by 195
Discovery of Thieno[3,2-d]pyrimidine-6-carboxamides as Potent Inhibitors of SIRT1, SIRT2, and SIRT3
Disch, J. S., Evindar, G., Chiu, C. H., Blum, C. A., Dai, H., Jin, L., Schuman, E., Lind, K. E., Belyanskaya, S. L., Deng, J., et al. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm400204k · Cited by 194
Hu, Y., He, Z., Li, Z., Wang, Y., Wu, N., Sun, H., Zhou, Z., Hu, Q., & Cong, X. (2024) · Clinical Epigenetics · doi:10.1186/s13148-024-01682-2 · Cited by 194
Foss, F., Advani, R., Duvic, M., Hymes, K. B., Intragumtornchai, T., Lekhakula, A., Shpilberg, O., Lerner, A., Belt, R. J., Jacobsen, E. D., et al. (2015) · British Journal of Haematology · doi:10.1111/bjh.13222 · Cited by 193
METTL3 Inhibitors for Epitranscriptomic Modulation of Cellular Processes
Moroz‐Omori, E. V., Huang, D., Kumar Bedi, R., Cheriyamkunnel, S. J., Bochenkova, E., Dolbois, A., Rzeczkowski, M. D., Li, Y., Wiedmer, L., & Caflisch, A. (2021) · ChemMedChem · doi:10.1002/cmdc.202100291 · Cited by 192
Treatment Effects of Low-Dose Theophylline Combined With an Inhaled Corticosteroid in COPD
Ford, P. A., Durham, A. L., Russell, R. E. K., Gordon, F., Adcock, I. M., & Barnes, P. J. (2010) · Chest · doi:10.1378/chest.09-2363 · Cited by 190
Bousiges, O., Vasconcelos, A. P. D., Neidl, R., Cosquer, B., Herbeaux, K., Panteleeva, I., Loeffler, J.-P., Cassel, J.-C., & Boutillier, A.-L. (2010) · Neuropsychopharmacology · doi:10.1038/npp.2010.117 · Cited by 189
Radiotherapy-Triggered Proteolysis Targeting Chimera Prodrug Activation in Tumors
Yang, C., Yang, Y., Li, Y., Ni, Q., & Li, J. (2023) · Journal of the American Chemical Society · doi:10.1021/jacs.2c10177 · Cited by 188
SMARCA4 loss is synthetic lethal with CDK4/6 inhibition in non-small cell lung cancer
Xue, Y., Meehan, B., Fu, Z., Wang, X. Q. D., Fiset, P. O., Rieker, R., Levins, C., Kong, T., Zhu, X., Morin, G., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-08380-1 · Cited by 187
Younes, A., Berdeja, J. G., Patel, M. R., Flinn, I., Gerecitano, J. F., Neelapu, S. S., Kelly, K. R., Copeland, A. R., Akins, A., Clancy, M. S., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00584-7 · Cited by 186
Selberg, S., Blokhina, D., Aatonen, M., Koivisto, P., Siltanen, A., Mervaala, E., Kankuri, E., & Karelson, M. (2019) · Cell Reports · doi:10.1016/j.celrep.2019.02.100 · Cited by 186
Rational Chemical Design of Molecular Glue Degraders
Toriki, E. S., Papatzimas, J. W., Nishikawa, K., Dovala, D., Frank, A. O., Hesse, M. J., Dankova, D., Song, J.-G., Bruce-Smythe, M., Struble, H., et al. (2023) · ACS Central Science · doi:10.1021/acscentsci.2c01317 · Cited by 184
Wang, F., Jin, Y., Wang, M., Luo, H.-Y., Fang, W.-J., Wang, Y.-N., Chen, Y.-X., Huang, R.-J., Guan, W.-L., Li, J.-B., et al. (2024) · Nature Medicine · doi:10.1038/s41591-024-02813-1 · Cited by 183
Jabbour, E., Short, N. J., Montalban-Bravo, G., Huang, X., Bueso-Ramos, C., Qiao, W., Yang, H., Zhao, C., Kadia, T., Borthakur, G., et al. (2017) · Blood · doi:10.1182/blood-2017-06-788497 · Cited by 182
Peng, X.-X., Yu, R., Wu, X., Wu, S.-Y., Pi, C., Chen, Z.-H., Zhang, X.-C., Gao, C.-Y., Shao, Y. W., Liu, L., et al. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2019-000376 · Cited by 182
Tudor: a versatile family of histone methylation ‘readers’
Lu, R., & Wang, G. G. (2013) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2013.08.002 · Cited by 181
Epigenetic regulation of early human embryo development
Wilkinson, A. L., Zorzan, I., & Rugg‐Gunn, P. J. (2023) · Cell stem cell · doi:10.1016/j.stem.2023.09.010 · Cited by 179
Inhibition of YTHDF2 triggers proteotoxic cell death in MYC-driven breast cancer
Einstein, J. M., Perelis, M., Chaim, I. A., Meena, J. K., Nussbacher, J. K., Tankka, A. T., Yee, B. A., Li, H., Madrigal, A. A., Neill, N. J., et al. (2021) · Molecular Cell · doi:10.1016/j.molcel.2021.06.014 · Cited by 178
The PEMDAC phase 2 study of pembrolizumab and entinostat in patients with metastatic uveal melanoma
Ny, L., Jespersen, H., Karlsson, J., Alsén, S., Filges, S., All-Eriksson, C., Andersson, B., Carneiro, A., Helgadottir, H., Levin, M., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-25332-w · Cited by 177
Targeted degradation of the enhancer lysine acetyltransferases CBP and p300
Vannam, R., Sayilgan, J., Ojeda, S., Karakyriakou, B., Hu, E., Kreuzer, J., Morris, R., Herrera Lopez, X. I., Rai, S., Haas, W., et al. (2021) · Cell Chemical Biology · doi:10.1016/j.chembiol.2020.12.004 · Cited by 177
Trapp, J., Jochum, A., Meier, R., Saunders, L. R., Marshall, B. L., Kunick, C., Verdin, E. M., Goekjian, P. G., Sippl, W., & Jung, M. (2006) · Journal of Medicinal Chemistry · doi:10.1021/jm060118b · Cited by 176
p300-mediated Acetylation of Histone H3 Lysine 56 Functions in DNA Damage Response in Mammals
Vempati, R. K., Jayani, R. S., Notani, D., Sengupta, A., Galande, S., & Haldar, D. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.149393 · Cited by 175
Süssmuth, S. D., Haider, S., Landwehrmeyer, G. B., Farmer, R., Frost, C., Tripepi, G., Andersen, C. A., Di Bacco, M., Lamanna, C., Diodato, E., et al. (2015) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.12512 · Cited by 175
Peng, F., Liao, M., Jin, W., Liu, W., Li, Z., Fan, Z., Zou, L., Chen, S., Zhu, L., Zhao, Q., et al. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01816-1 · Cited by 175
Nicholls, S. J., Gordon, A., Johansson, J., Wolski, K., Ballantyne, C. M., Kastelein, J. J. P., Taylor, A., Borgman, M., & Nissen, S. E. (2011) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2010.11.015 · Cited by 174
The many lives of KATs — detectors, integrators and modulators of the cellular environment
Sheikh, B. N., & Akhtar, A. (2019) · Nature Reviews Genetics · doi:10.1038/s41576-018-0072-4 · Cited by 172
Malacrida, A., Rivara, M., Di Domizio, A., Cislaghi, G., Miloso, M., Zuliani, V., & Nicolini, G. (2020) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2019.115300 · Cited by 172
Enasidenib: First Global Approval
Kim, E. S. (2017) · Drugs · doi:10.1007/s40265-017-0813-2 · Cited by 171
Haven't got a glue: Protein surface variation for the design of molecular glue degraders
Kozicka, Z., & Thomä, N. H. (2021) · Cell Chemical Biology · doi:10.1016/j.chembiol.2021.04.009 · Cited by 170
Tao, Y., Kang, B., Petkovich, D. A., Bhandari, Y. R., In, J., Stein-O'Brien, G., Kong, X., Xie, W., Zachos, N., Maegawa, S., et al. (2019) · Cancer Cell · doi:10.1016/j.ccell.2019.01.005 · Cited by 170
Emerging degrader technologies engaging lysosomal pathways
Ding, Y., Xing, D., Fei, Y., & Lu, B. (2022) · Chemical Society Reviews · doi:10.1039/d2cs00624c · Cited by 170
Yang, Y., Yan, Y., Yin, J., Tang, N., Wang, K., Huang, L., Hu, J., Feng, Z., Gao, Q., & Huang, A. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01316-8 · Cited by 170
Energy-driven genome regulation by ATP-dependent chromatin remodellers
Eustermann, S., Patel, A. B., Hopfner, K., He, Y., & Korber, P. (2023) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-023-00683-y · Cited by 170
Gong, N., Teng, X., Li, J., & Liang, X.-J. (2019) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.8b18288 · Cited by 169
1,4,9-Triazaspiro[5.5]undecan-2-one Derivatives as Potent and Selective METTL3 Inhibitors
Dolbois, A., Bedi, R. K., Bochenkova, E., Müller, A., Moroz, E., Danzhi Huang, A., & Caflisch, A. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c00773 · Cited by 169
Palmer, W. S., Poncet-Montange, G., Liu, G., Petrocchi, A., Reyna, N., Subramanian, G., Theroff, J., Yau, A., Kost-Alimova, M., Bardenhagen, J. P., et al. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b00405 · Cited by 168
Tommasini-Ghelfi, S., Murnan, K., Kouri, F. M., Mahajan, A. S., May, J. L., & Stegh, A. H. (2019) · Science Advances · doi:10.1126/sciadv.aaw4543 · Cited by 168
Lysine Demethylase KDM6A in Differentiation, Development, and Cancer
Tran, N., Broun, A., & Ge, K. (2020) · Molecular and Cellular Biology · doi:10.1128/mcb.00341-20 · Cited by 168
Methylation across the central dogma in health and diseases: new therapeutic strategies
Liu, R., Zhao, E., Yu, H., Yuan, C., Abbas, M. N., & Cui, H. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01528-y · Cited by 168
Reza, A. M. M. T., Choi, Y., Han, S. G., Song, H., Park, C., Hong, K., & Kim, J. (2018) · Biological reviews/Biological reviews of the Cambridge Philosophical Society · doi:10.1111/brv.12459 · Cited by 167
Small‐Molecule Inhibitors of METTL3, the Major Human Epitranscriptomic Writer
Bedi, R. K., Huang, D., Eberle, S. A., Wiedmer, L., Śledź, P., & Caflisch, A. (2020) · ChemMedChem · doi:10.1002/cmdc.202000011 · Cited by 167
Liu, Y., Guo, Q., Yang, H., Zhang, X.-W., Feng, N., Wang, J.-K., Liu, T., Zeng, K., & Tu, P. (2022) · ACS Central Science · doi:10.1021/acscentsci.2c00107 · Cited by 167
The IGF2BP family of RNA binding proteins links epitranscriptomics to cancer
Ramesh-Kumar, D., & Guil, S. (2022) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2022.05.009 · Cited by 167
Zhou, L., Jiang, J., Huang, Z., Jin, P., Peng, L., Luo, M., Zhang, Z., Chen, Y., Xie, N., Gao, W., et al. (2022) · Molecular Cancer · doi:10.1186/s12943-022-01638-1 · Cited by 167
Izutsu, K., Makita, S., Nosaka, K., Yoshimitsu, M., Utsunomiya, A., Kusumoto, S., Morishima, S., Tsukasaki, K., Kawamata, T., Ono, T., et al. (2023) · Blood · doi:10.1182/blood.2022016862 · Cited by 167
Gunst, J. D., Pahus, M. H., Rosás-Umbert, M., Lu, I., Benfield, T., Nielsen, H. I., Johansen, I. S., Mohey, R., Østergaard, L. J., Klastrup, V., et al. (2022) · Nature Medicine · doi:10.1038/s41591-022-02023-7 · Cited by 167
Romidepsin: a novel histone deacetylase inhibitor for cancer
Bertino, E. M., & Otterson, G. A. (2011) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2011.594437 · Cited by 166
Piha-Paul, S. A., Sachdev, J. C., Barve, M. A., LoRusso, P. M., Szmulewitz, R. Z., Patel, S. P., Lara, P. N., Chen, X., Hu, B., Freise, K. J., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-0578 · Cited by 166
Ray, K. K., Nicholls, S. J., Buhr, K. A., Ginsberg, H. N., Johansson, J. O., Kalantar-Zadeh, K., Kulikowski, E., Toth, P. P., Wong, N., Sweeney, M., et al. (2020) · JAMA · doi:10.1001/jama.2020.3308 · Cited by 166
Tap, W. D., Villalobos, V. M., Cote, G. M., Burris, H., Janku, F., Mir, O., Beeram, M., Wagner, A. J., Jiang, L., Wu, B., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.19.02492 · Cited by 165
Hore, T. A., von Meyenn, F., Ravichandran, M., Bachman, M., Ficz, G., Oxley, D., Santos, F., Balasubramanian, S., Jurkowski, T. P., & Reik, W. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1608679113 · Cited by 165
Yap, T. A., Winter, J. N., Giulino-Roth, L., Longley, J., Lopez, J., Michot, J.-M., Leonard, J. P., Ribrag, V., McCabe, M. T., Creasy, C. L., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-4121 · Cited by 165
Molecular basis of nucleosomal H3K36 methylation by NSD methyltransferases
Li, W., Tian, W., Yuan, G., Deng, P., Sengupta, D., Cheng, Z., Cao, Y., Ren, J., Qin, Y., Zhou, Y., et al. (2020) · Nature · doi:10.1038/s41586-020-03069-8 · Cited by 165
Epigenetic modification of m6A regulator proteins in cancer
Wang, Y., Wang, Y., Patel, H., Chen, J., Wang, J., Chen, Z.-S., & Wang, H. (2023) · Molecular Cancer · doi:10.1186/s12943-023-01810-1 · Cited by 165
Regulation of DNA Methylation in Rheumatoid Arthritis Synoviocytes
Nakano, K., Boyle, D. L., & Firestein, G. S. (2013) · The Journal of Immunology · doi:10.4049/jimmunol.1202572 · Cited by 164
Efficiency and Target Derepression of Anti-miR-92a: Results of a First in Human Study
Abplanalp, W. T., Fischer, A., John, D., Zeiher, A. M., Gosgnach, W., Darville, H., Montgomery, R. L., Pestano, L. A., Allée, G., Paty, I., et al. (2020) · Nucleic Acid Therapeutics · doi:10.1089/nat.2020.0871 · Cited by 164
m6A-RNA Demethylase FTO Inhibitors Impair Self-Renewal in Glioblastoma Stem Cells
Huff, S., Tiwari, S. K., Gonzalez, G. M., Wang, Y., & Rana, T. M. (2021) · ACS Chemical Biology · doi:10.1021/acschembio.0c00841 · Cited by 164
LP99: Discovery and Synthesis of the First Selective BRD7/9 Bromodomain Inhibitor
Clark, P. G. K., Vieira, L. C. C., Tallant, C., Fedorov, O., Singleton, D. C., Rogers, C. M., Monteiro, O. P., Bennett, J. M., Baronio, R., Müller, S., et al. (2015) · Angewandte Chemie International Edition · doi:10.1002/anie.201501394 · Cited by 164
Cosío, B. G., Iglesias, A., Rios, A., Noguera, A., Sala, E., Ito, K., Barnes, P. J., & Agustí, A. G. N. (2009) · Thorax · doi:10.1136/thx.2008.103432 · Cited by 163
Selective PROTAC-mediated degradation of SMARCA2 is efficacious in SMARCA4 mutant cancers
Cantley, J. L., Ye, X., Rousseau, E., Januario, T., Hamman, B. D., Rose, C. M., Cheung, T. K., Hinkle, T. B., Soto, L., Quinn, C., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-34562-5 · Cited by 163
Mahapatra, L., Andruska, N., Mao, C., Le, J., & Shapiro, D. J. (2017) · Translational Oncology · doi:10.1016/j.tranon.2017.07.008 · Cited by 162
Asymmetric Expression of LincGET Biases Cell Fate in Two-Cell Mouse Embryos
Wang, J., Wang, L., Feng, G., Wang, Y., Li, Y., Li, X., Liu, C., Jiao, G., Huang, C., Shi, J., et al. (2018) · Cell · doi:10.1016/j.cell.2018.11.039 · Cited by 162
Yang, G., Wang, W., Mok, S. W. F., Wu, C., Law, B. Y. K., Miao, X., Wu, K., Zhong, H., Wong, C., Wong, V. K. W., et al. (2018) · Angewandte Chemie International Edition · doi:10.1002/anie.201807305 · Cited by 161
Gimsing, P., Hansen, M., Knudsen, L. M., Knoblauch, P., Christensen, I. J., Ooi, C. E., & Buhl‐Jensen, P. (2008) · European Journal of Haematology · doi:10.1111/j.1600-0609.2008.01102.x · Cited by 160
Clinical and biological effects of demethylating agents on solid tumours – A systematic review
Linnekamp, J. F., Butter, R., Spijker, R., Medema, J. P., & van Laarhoven, H. W. M. (2017) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2017.01.004 · Cited by 160
Mercuri, E. M., Vilchez, J. J., Boespflug‐Tanguy, O., Zaidman, C. M., Mah, J. K., Goemans, N., Müller‐Felber, W., Niks, E. H., Schara, U., Bertini, E., et al. (2024) · The Lancet Neurology · doi:10.1016/s1474-4422(24)00036-x · Cited by 160
YEATS2 links histone acetylation to tumorigenesis of non-small cell lung cancer
Mi, W., Guan, H., Lyu, J., Zhao, D., Xi, Y., Jiang, S., Andrews, F. H., Wang, X., Gagea, M., Wen, H., et al. (2017) · Nature Communications · doi:10.1038/s41467-017-01173-4 · Cited by 159
Plant Growth Regulator Daminozide Is a Selective Inhibitor of Human KDM2/7 Histone Demethylases
Rose, N. R., Woon, E. C. Y., Tumber, A., Walport, L. J., Chowdhury, R., Li, X. S., King, O. N. F., Lejeune, C., Ng, S. S., Krojer, T., et al. (2012) · Journal of Medicinal Chemistry · doi:10.1021/jm300677j · Cited by 159
Phenyl‐Glutarimides: Alternative Cereblon Binders for the Design of PROTACs
Min, J., Mayasundari, A., Keramatnia, F., Jonchere, B., Yang, S. W., Jarusiewicz, J., Actis, M., Das, S., Young, B., Slavish, J., et al. (2021) · Angewandte Chemie International Edition · doi:10.1002/anie.202108848 · Cited by 159
KDM7 is a dual demethylase for histone H3 Lys 9 and Lys 27 and functions in brain development
Tsukada, Y.-I., Ishitani, T., & Nakayama, K. I. (2010) · Genes & Development · doi:10.1101/gad.1864410 · Cited by 158
Arce, C., Pérez‐Plasencia, C., González‐Fierro, A., la Cruz-Hernández, E. N. D., Vázquez, A. L. R., Chávez-Blanco, A. D., Trejo‐Becerril, C., Pérez‐Cárdenas, E., Taja‐Chayeb, L., Bargalló, E., et al. (2006) · PLoS ONE · doi:10.1371/journal.pone.0000098 · Cited by 158
Miguel, J. F. S., Hungria, V., Yoon, S., Beksaç, M., Dimopoulos, M. A., Elghandour, A., Wiktor-Jędrzejczak, W., Guenther, A., Nakorn, T. N., Siritanaratkul, N., et al. (2016) · The Lancet Haematology · doi:10.1016/s2352-3026(16)30147-8 · Cited by 158
Kantarjian, H. M., Roboz, G. J., Kropf, P. L., Yee, K. W. L., O'Connell, C. L., Tibes, R., Walsh, K. J., Podoltsev, N. A., Griffiths, E. A., Jabbour, E., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30576-4 · Cited by 158
Brehmer, D., Beke, L., Wu, T., Millar, H. J., Moy, C., Sun, W., Mannens, G., Pande, V., Boeckx, A., van Heerde, E., et al. (2021) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-21-0367 · Cited by 158
Zauderer, M. G., Szlosarek, P. W., Moulec, S. L., Popat, S., Taylor, P., Planchard, D., Scherpereel, A., Koczywas, M., Forster, M. D., Cameron, R. B., et al. (2022) · The Lancet Oncology · doi:10.1016/s1470-2045(22)00277-7 · Cited by 158
Pili, R., Salumbides, B., Zhao, M., Altiok, S., Qian, D., Zwiebel, J., Carducci, M. A., & Rudek, M. A. (2012) · British Journal of Cancer · doi:10.1038/bjc.2011.527 · Cited by 157
SIRT7 antagonizes human stem cell aging as a heterochromatin stabilizer
Bi, S., Liu, Z., Wu, Z., Wang, Z., Liu, X., Wang, S., Ren, J., Yao, Y., Zhang, W., Song, M., et al. (2020) · Protein & Cell · doi:10.1007/s13238-020-00728-4 · Cited by 157
Anastasiadou, E., Seto, A. G., Beatty, X., Hermreck, M., Gilles, M.-E., Stroopinsky, D., Pinter-Brown, L. C., Pestano, L., Marchese, C., Avigan, D., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-3139 · Cited by 157
Tumber, A., Nuzzi, A., Hookway, E. S., Hatch, S. B., Velupillai, S., Johansson, C., Kawamura, A., Savitsky, P. A., Yapp, C., Szykowska, A., et al. (2017) · Cell chemical biology · doi:10.1016/j.chembiol.2017.02.006 · Cited by 154
Wei, S., Zhang, J., Zhao, R., Shi, R., An, L., Yu, Z., Zhang, Q., Zhang, J., Yao, Y., Li, H., et al. (2024) · Cell Death Discovery · doi:10.1038/s41420-024-01898-4 · Cited by 154
Self-citationDragovich, P. S., Pillow, T. H., Blake, R. A., Sadowsky, J. D., Adaligil, E., Adhikari, P., Bhakta, S., Blaquiere, N., Chen, J., dela Cruz-Chuh, J., et al. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c01845 · Cited by 152
Zhang, J., Gao, Q., Li, P., Liu, X., Jia, Y., Wu, W., Li, J., Dong, S., Koseki, H., & Wong, J. (2011) · Cell Research · doi:10.1038/cr.2011.176 · Cited by 152
Smith, M. R., Syed, A., Lukacsovich, T., Purcell, J., Barbaro, B. A., Worthge, S. A., Wei, S. R., Pollio, G., Magnoni, L., Scali, C., et al. (2014) · Human Molecular Genetics · doi:10.1093/hmg/ddu010 · Cited by 151
Self-citationBitzer, M., Horger, M., Giannini, E. G., Ganten, T. M., Wörns, M., Siveke, J. T., Dollinger, M., Gerken, G., Scheulen, M. E., Wege, H., et al. (2016) · Journal of Hepatology · doi:10.1016/j.jhep.2016.02.043 · Cited by 151
DOT1L inhibition reveals a distinct subset of enhancers dependent on H3K79 methylation
Godfrey, L., Crump, N. T., Thorne, R., Lau, I.-J., Repapi, E., Dimou, D., Smith, A. L., Harman, J. R., Telenius, J. M., Oudelaar, A. M., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-10844-3 · Cited by 151
Guirguis, A. A., Ofir-Rosenfeld, Y., Knezevic, K., Blackaby, W., HARDICK, D. J., Chan, Y.-C., Motazedian, A., Gillespie, A., Vassiliadis, D., Lam, E. Y. N., et al. (2023) · Cancer Discovery · doi:10.1158/2159-8290.cd-23-0007 · Cited by 151
de Botton, S., Fenaux, P., Yee, K. W. L., Récher, C., Wei, A. H., Montesinos, P., Taussig, D. C., Pigneux, A., Braun, T., Curti, A., et al. (2023) · Blood Advances · doi:10.1182/bloodadvances.2022009411 · Cited by 150
Lachowiez, C. A., Loghavi, S., Zeng, Z., Tanaka, T. N., Kim, Y. J., Uryu, H., Turkalj, S., Jakobsen, N. A., Luskin, M. R., Duose, D. Y., et al. (2023) · Blood Cancer Discovery · doi:10.1158/2643-3230.bcd-22-0205 · Cited by 150
DNA Methylation in Systemic Lupus Erythematosus
Hedrich, C. M., Mäbert, K., Rauen, T., & Tsokos, G. C. (2016) · Epigenomics · doi:10.2217/epi-2016-0096 · Cited by 149
Gnanapragasam, M. N., Scarsdale, J. N., Amaya, M. L., Webb, H. D., Desai, M. A., Walavalkar, N. M., Wang, S. Z., Zu Zhu, S., Ginder, G. D., & Williams, D. C. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1015341108 · Cited by 148
Wang, T., Hong, T., Huang, Y., Su, H., Wu, F., Chen, Y., Wei, L., Huang, W., Hua, X., Yu, X., et al. (2015) · Journal of the American Chemical Society · doi:10.1021/jacs.5b06690 · Cited by 147
Structure of nucleosome-bound DNA methyltransferases DNMT3A and DNMT3B
Xu, T.-H., Liu, M., Zhou, X. E., Liang, G., Zhao, G., Xu, H. E., Melcher, K., & Jones, P. A. (2020) · Nature · doi:10.1038/s41586-020-2747-1 · Cited by 146
Therapeutic targeting of EP300/CBP by bromodomain inhibition in hematologic malignancies
Nicosia, L., Spencer, G. J., Brooks, N. A. N., Amaral, F. M. R., Basma, N. J., Chadwick, J. A., Revell, B., Wingelhofer, B., Maiqués-Díaz, A., Sinclair, O. J., et al. (2023) · Cancer Cell · doi:10.1016/j.ccell.2023.11.001 · Cited by 146
Kanouni, T., Severin, C., Cho, R. W., Yuen, N., Xu, J., Shi, L., Lai, C., Rosario, J. R. D., Stansfield, R. K., Lawton, L. N., et al. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c00978 · Cited by 145
Wang, F., Morita, K., Dinardo, C. D., Furudate, K., Tanaka, T. N., Yan, Y., Patel, K. P., MacBeth, K. J., Wu, B., Liu, G., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-22874-x · Cited by 145
Kung, P., Bingham, P., Brooun, A., Collins, M. R., Deng, Y., Dinh, D. M., Fan, C., Gajiwala, K. S., Grantner, R., Gukasyan, H. J., et al. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b01375 · Cited by 144
Methyltransferase-like proteins in cancer biology and potential therapeutic targeting
Qi, Y., Liu, Z., Hong, L., Li, P., & Ling, Z. (2023) · Journal of Hematology & Oncology · doi:10.1186/s13045-023-01477-7 · Cited by 144
Aggarwal, R. R., Schweizer, M. T., Nanus, D. M., Pantuck, A. J., Heath, E. I., Campeau, E., Attwell, S., Norek, K., Snyder, M., Bauman, L. A., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-1707 · Cited by 143
de Botton, S., Montesinos, P., Schuh, A. C., Papayannidis, C., Vyas, P., Wei, A. H., Ommen, H. B., Семочкин, С. В., Kim, H., Larson, R. A., et al. (2022) · Blood · doi:10.1182/blood.2021014901 · Cited by 143
Structural Basis for Acetylated Histone H4 Recognition by the Human BRD2 Bromodomain
Umehara, T., Nakamura, Y., Jang, M. K., Nakano, K., Tanaka, A., Ozato, K., Padmanabhan, B., & Yokoyama, S. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.062422 · Cited by 142
Tang, X., Li, X., Zhang, D., & Han, W. (2022) · Bioengineered · doi:10.1080/21655979.2022.2049471 · Cited by 142
Transcriptional Repression and Heterochromatin Formation by MBD1 and MCAF/AM Family Proteins
Ichimura, T., Watanabe, S., Sakamoto, Y., Aoto, T., Fujita, N., & Nakao, M. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m413654200 · Cited by 141
Fedorov, O., Castex, J., Tallant, C., Owen, D. R., Martin, S., Aldeghi, M., Monteiro, O., Filippakopoulos, P., Picaud, S., Trzupek, J. D., et al. (2015) · Science Advances · doi:10.1126/sciadv.1500723 · Cited by 141
Norsworthy, K. J., Luo, L., Hsu, V., Gudi, R., Dorff, S. E., Przepiorka, D., Deisseroth, A., Shen, Y. L., Sheth, C. M., Charlab, R., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-3749 · Cited by 141
Chen, J., Xu, C., Yang, K., Gao, R., Cao, Y., Liang, L., Chen, S., Xu, S., Rong, R., Wang, J., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-36747-y · Cited by 141
CARM1 and Paraspeckles Regulate Pre-implantation Mouse Embryo Development
Hupalowska, A., Jedrusik, A., Zhu, M., Bedford, M. T., Glover, D. M., & Zernicka-Goetz, M. (2018) · Cell · doi:10.1016/j.cell.2018.11.027 · Cited by 139
Decrypting noncoding RNA interactions, structures, and functional networks
Fabbri, M., Girnita, L., Varani, G., & Calin, G. A. (2019) · Genome Research · doi:10.1101/gr.247239.118 · Cited by 139
Bosch-Presegué, L., Raurell-Vila, H., Marazuela-Duque, A., Kane-Goldsmith, N., Valle, A., Oliver, J., Serrano, L., & Vaquero, A. (2011) · Molecular Cell · doi:10.1016/j.molcel.2011.02.034 · Cited by 138
Coronel, J., Cetina, L., Pacheco‐Bravo, I., Trejo‐Becerril, C., González‐Fierro, A., la Cruz-Hernández, E. N. D., Pérez‐Cárdenas, E., Taja‐Chayeb, L., Arias-Bofill, D., Candelaria, M., et al. (2010) · Medical Oncology · doi:10.1007/s12032-010-9700-3 · Cited by 138
Sayegh, J., Cao, J. P., Zou, M. R., Morales, A., Blair, L. P., Norcia, M., Hoyer, D., Tackett, A. J., Merkel, J. S., & Yan, Q. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.419861 · Cited by 138
Klaus, C. R., Iwanowicz, D., Johnston, D., Campbell, C. T., Smith, J. J., Moyer, M. P., Copeland, R. A., Olhava, E. J., Scott, M. P., Pollock, R. M., et al. (2014) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.114.214577 · Cited by 137
Chronic Oral Administration of CI-994: A Phase I Study
Prakash, S., Foster, B. J., Meyer, M., Wozniak, A., Heilbrun, L. K., Flaherty, L. E., Zalupski, M. M., Radulovic, L. L., Valdivieso, M., & LoRusso, P. M. (2001) · Investigational New Drugs · doi:10.1023/a:1006489328324 · Cited by 136
SIRT6 exhibits nucleosome-dependent deacetylase activity
Gil, R., Barth, S., Kanfi, Y., & Cohen, H. Y. (2013) · Nucleic Acids Research · doi:10.1093/nar/gkt642 · Cited by 136
Oki, Y., Kelly, K. R., Flinn, I. W., Patel, M. R., Gharavi, R. B., Ma, A., Parker, J., Hafeez, A., Tuck, D. P., & Younes, A. (2017) · Haematologica · doi:10.3324/haematol.2017.172882 · Cited by 136
Mahfouz, R. Z., Jankowska, A., Ebrahem, Q., Gu, X., Visconte, V., Tabarroki, A., Terse, P., Covey, J., Chan, K., Ling, Y., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-1722 · Cited by 135
New advances of adiponectin in regulating obesity and related metabolic syndromes
Han, Y., Sun, Q., Chen, W., Gao, Y., Ye, J., Chen, Y., Wang, T., Gao, L., Liu, Y., & Yang, Y. (2023) · Journal of Pharmaceutical Analysis · doi:10.1016/j.jpha.2023.12.003 · Cited by 135
Synthesis of a FTO Inhibitor with Anticonvulsant Activity
Zheng, G., Cox, T., Tribbey, L., Wang, G. Z., Iacoban, P., Booher, M. E., Gabriel, G. J., Zhou, L., Bae, N. S., Rowles, J., et al. (2014) · ACS Chemical Neuroscience · doi:10.1021/cn500042t · Cited by 134
Toh, J. D. W., Sun, L., Lau, L. Z. M., Tan, J., Low, J. J. A., Tang, C. W. Q., Cheong, E. J. Y., Tan, M. J. H., Chen, Y., Hong, W., et al. (2014) · Chemical Science · doi:10.1039/c4sc02554g · Cited by 134
Targeting miRNA by CRISPR/Cas in cancer: advantages and challenges
Hussen, B. M., Rasul, M. F., Abdullah, S. R., Hidayat, H. J., Faraj, G. S. H., Ali, F. A., Salihi, A. B., Baniahmad, A., Ghafouri‐Fard, S., Rahman, M., et al. (2023) · Military Medical Research · doi:10.1186/s40779-023-00468-6 · Cited by 134
Intravenous Vitamin C for Cancer Therapy – Identifying the Current Gaps in Our Knowledge
Carr, A. C., & Cook, J. (2018) · Frontiers in Physiology · doi:10.3389/fphys.2018.01182 · Cited by 133
Tranylcypromine Based Lysine-Specific Demethylase 1 Inhibitor: Summary and Perspective
Dai, X., Liu, Y., Xiong, X.-P., Xue, L.-P., Zheng, Y., & Liu, H. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c00919 · Cited by 133
Hellmann, M. D., Jänne, P. A., Opyrchal, M., Hafez, N., Raez, L. E., Gabrilovich, D. I., Wang, F., Trepel, J. B., Lee, M.-J., Yuno, A., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-3305 · Cited by 133
Comprehensive review for anticancer hybridized multitargeting HDAC inhibitors
Bass, A. K. A., El‐Zoghbi, M. S., Nageeb, E.-S. M., Mohamed, M. F. A., Badr, M., & Abuo‐Rahma, G. E. A. (2020) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2020.112904 · Cited by 132
He, Y., Zheng, Z., Liu, C., Li, W., Zhao, L., Nie, G., & Li, H. (2021) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2021.11.002 · Cited by 132
Mechanisms of action and resistance in histone methylation-targeted therapy
Yamagishi, M., Kuze, Y., Kobayashi, S., Nakashima, M., Morishima, S., Kawamata, T., Makiyama, J., Suzuki, K., Seki, M., Abe, K., et al. (2024) · Nature · doi:10.1038/s41586-024-07103-x · Cited by 132
Kummar, S., Gutierrez, M., Gardner, E. R., Donovan, E., Hwang, K., Chung, E. J., Lee, M.-J., Maynard, K., Kalnitskiy, M., Chen, A., et al. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-0791 · Cited by 131
Advances in histone demethylase KDM4 as cancer therapeutic targets
Lee, D. H., Kim, G. W., Jeon, Y. H., Yoo, J., Lee, S. W., & Kwon, S. H. (2020) · The FASEB Journal · doi:10.1096/fj.201902584r · Cited by 131
Salamero, O., Montesinos, P., Willekens, C., Pérez‐Simón, J. A., Pigneux, A., Récher, C., Popat, R., Carpio, C. D. C., Molinero, C., Mascaró, C., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.19.03250 · Cited by 131
O-GlcNAcylation determines the translational regulation and phase separation of YTHDF proteins
Chen, Y., Wan, R., Zou, Z., Lao, L., Shao, G., Zheng, Y., Tang, L. L., Yuan, Y., Ge, Y., He, C., et al. (2023) · Nature Cell Biology · doi:10.1038/s41556-023-01258-x · Cited by 131
Adès, L., Girshova, L., Doronin, V. A., Díez-Campelo, M., Valcárcel, D., Kambhampati, S., Viniou, N.-A., Woszczyk, D., De Paz Arias, R., Symeonidis, A., et al. (2022) · Blood Advances · doi:10.1182/bloodadvances.2022007334 · Cited by 130
Watts, J. M., Baer, M. R., Yang, J., Prébet, T., Lee, S., Schiller, G. J., Dinner, S. N., Pigneux, A., Montesinos, P., Wang, E. S., et al. (2022) · The Lancet Haematology · doi:10.1016/s2352-3026(22)00292-7 · Cited by 130
Finazzi, G., Vannucchi, A. M., Martinelli, V., Ruggeri, M., Nobile, F., Specchia, G., Pogliani, E. M., Olimpieri, O. M., Fioritoni, G., Musolino, C., et al. (2013) · British Journal of Haematology · doi:10.1111/bjh.12332 · Cited by 128
Zhao, B., Yang, Y., Wang, X., Chong, Z., Yin, R., Song, S.-H., Zhao, C., Li, C., Huang, H., Sun, B.-F., et al. (2014) · Nucleic Acids Research · doi:10.1093/nar/gkt1090 · Cited by 128
Shapiro, G. I., LoRusso, P. M., Dowlati, A., Do, K. T., Jacobson, C. A., Vaishampayan, U. N., Weise, A. M., Caimi, P. F., Eder, J. P., French, C. A., et al. (2020) · British Journal of Cancer · doi:10.1038/s41416-020-01180-1 · Cited by 128
Pharmaceutical strategies for endoplasmic reticulum-targeting and their prospects of application
Shi, Y., Wang, S., Wu, J., Jin, X., & You, J. (2020) · Journal of Controlled Release · doi:10.1016/j.jconrel.2020.11.054 · Cited by 127
Rational Design of Novel Anticancer Small-Molecule RNA m6A Demethylase ALKBH5 Inhibitors
Selberg, S., Seli, N., Kankuri, E. M., & Karelson, M. M. (2021) · ACS Omega · doi:10.1021/acsomega.1c01289 · Cited by 127
Disease-associated astrocyte epigenetic memory promotes CNS pathology
Lee, H.-G., Rone, J. M., Li, Z., Akl, C. F., Shin, S. W., Lee, J.-H., Flausino, L. E., Pernin, F., Chao, C.-C., Kleemann, K. L., et al. (2024) · Nature · doi:10.1038/s41586-024-07187-5 · Cited by 127
Connolly, R. M., Zhao, F., Miller, K. D., Lee, M.-J., Piekarz, R. L., Smith, K. L., Brown-Glaberman, U. A., Winn, J. S., Faller, B. A., Onitilo, A. A., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.21.00944 · Cited by 125
Structural Basis for Hydroxymethylcytosine Recognition by the SRA Domain of UHRF2
Zhou, T., Xiong, J., Wang, M., Yang, N., Wong, J., Zhu, B., & Xu, R.-M. (2014) · Molecular Cell · doi:10.1016/j.molcel.2014.04.003 · Cited by 125
Han, X., Liu, L., Huang, S., Xiao, W., Gao, Y., Zhou, W., Zhang, C., Zheng, H., Yang, L., Xie, X., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-43219-w · Cited by 124
Therapeutic targeting of DNA methylation alterations in cancer
Lee, A. V., Nestler, K. A., & Chiappinelli, K. B. (2024) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2024.108640 · Cited by 124
LP99: Discovery and Synthesis of the First Selective BRD7/9 Bromodomain Inhibitor
Clark, P. G. K., Vieira, L. C. C., Tallant, C., Fedorov, O., Singleton, D. C., Rogers, C. M., Monteiro, O., Bennett, J. M., Baronio, R., Müller, S., et al. (2015) · Angewandte Chemie · doi:10.1002/ange.201501394 · Cited by 123
Fioravanti, R., Stazi, G., Zwergel, C., Valente, S., & Mai, A. (2018) · The Chemical Record · doi:10.1002/tcr.201800091 · Cited by 123
Buscarlet, M., Krasteva, V., Ho, L., Simon, C., Hébert, J., Wilhelm, B., Crabtree, G. R., Sauvageau, G., Thibault, P., & Lessard, J. A. (2014) · Blood · doi:10.1182/blood-2013-02-483495 · Cited by 122
Venugopal, B., Baird, R., Kristeleit, R. S., Plummer, R., Cowan, R., Stewart, A., Fourneau, N., Hellemans, P., Elsayed, Y., Mcclue, S., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-0312 · Cited by 122
DOT1L as a therapeutic target for the treatment of DNMT3A-mutant acute myeloid leukemia
Rau, R. E., Rodriguez, B. A., Luo, M., Jeong, M., Rosen, A., Rogers, J. H., Campbell, C. T., Daigle, S. R., Deng, L., Song, Y., et al. (2016) · Blood · doi:10.1182/blood-2015-11-684225 · Cited by 122
Mechanisms of Long Noncoding RNA Nuclear Retention
Guo, C., Xu, G., & Chen, L. (2020) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2020.07.001 · Cited by 121
Molecular Modeling and Molecular Dynamics Studies of Hydralazine with Human DNA Methyltransferase 1
Singh, N. P., Dueñas‐González, A., Lyko, F., & Medina‐Franco, J. L. (2009) · ChemMedChem · doi:10.1002/cmdc.200900017 · Cited by 120
Decitabine/Cedazuridine: First Approval
Dhillon, S. (2020) · Drugs · doi:10.1007/s40265-020-01389-7 · Cited by 120
Structure, Activity, and Function of PRMT1
Thiébaut, C., Eve, L., Poulard, C., & Romancer, M. L. (2021) · Life · doi:10.3390/life11111147 · Cited by 120
He, W., Zhou, B., Liu, W., Zhang, M., Shen, Z., Han, Z., Jiang, Q., Yang, Q., Song, C., Wang, R., et al. (2015) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b00702 · Cited by 119
Gore, S. D., Jones, C. A., & Kirkpatrick, P. N. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2180 · Cited by 119
Chronic myelomonocytic leukemia: 2024 update on diagnosis, risk stratification and management
Patnaik, M. M., & Tefferi, A. (2024) · American Journal of Hematology · doi:10.1002/ajh.27271 · Cited by 118
Xie, S., Zhu, J., Li, J., Zhan, F., Yao, H., Xu, J., & Xu, S. (2023) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.3c00736 · Cited by 117
Gerstenberger, B. S., Trzupek, J. D., Tallant, C., Fedorov, O., Filippakopoulos, P., Brennan, P. E., Fedele, V., Martin, S., Picaud, S., Rogers, C. M., et al. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b00012 · Cited by 116
Histone Methyltransferase SETDB1: A Common Denominator of Tumorigenesis with Therapeutic Potential
Strepkos, D., Markouli, M., Κλώνου, Α., Papavassiliou, A. G., & Piperi, C. (2021) · Cancer Research · doi:10.1158/0008-5472.can-20-2906 · Cited by 116
Targeting FTO induces colorectal cancer ferroptotic cell death by decreasing SLC7A11/GPX4 expression
Qiao, Y., Su, M., Zhao, H., Liu, H., Wang, C., Dai, X., Liu, L., Liu, G., Sun, H., Sun, M., et al. (2024) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-024-03032-9 · Cited by 116
Structural Insights into N 6 -Methyladenosine (m 6 A) Modification in the Transcriptome
Huang, J. B., & Yin, P. (2018) · Genomics Proteomics & Bioinformatics · doi:10.1016/j.gpb.2018.03.001 · Cited by 115
Stein, E. M., Fathi, A. T., Dinardo, C. D., Pollyea, D. A., Roboz, G. J., Collins, R. H., Sekeres, M. A., Stone, R. M., Attar, E. C., Frattini, M. G., et al. (2020) · The Lancet Haematology · doi:10.1016/s2352-3026(19)30284-4 · Cited by 115
Wass, M., Göllner, S., Besenbeck, B., Schlenk, R. F., Mundmann, P., Göthert, J. R., Noppeney, R., Schliemann, C., Mikesch, J., Lenz, G., et al. (2020) · Leukemia · doi:10.1038/s41375-020-0892-z · Cited by 115
Sekeres, M. A., Watts, J. M., Radinoff, A., Sangerman, M. A., Cerrano, M., Font, P., Zeidner, J. F., Díez‐Campelo, M., Graux, C., Liesveld, J. L., et al. (2021) · Leukemia · doi:10.1038/s41375-021-01125-4 · Cited by 115
Garcia‐Manero, G., McCloskey, J. K., Griffiths, E. A., Yee, K. W. L., Zeidan, A. M., Al‐Kali, A., Deeg, H. J., Patel, P. A., Sabloff, M., Keating, M., et al. (2023) · The Lancet Haematology · doi:10.1016/s2352-3026(23)00338-1 · Cited by 114
Blum, K. A., Advani, A., Fernandez, L., Van Der Jagt, R., Brandwein, J., Kambhampati, S., Kassis, J., Davis, M., Bonfils, C., Dubay, M., et al. (2009) · British Journal of Haematology · doi:10.1111/j.1365-2141.2009.07881.x · Cited by 113
IDH inhibition in gliomas: from preclinical models to clinical trials
Rudà, R., Horbinski, C., van den Bent, M. J., Preusser, M., & Soffietti, R. (2024) · Nature Reviews Neurology · doi:10.1038/s41582-024-00967-7 · Cited by 113
Epigenetic suppression of neuroligin 1 underlies amyloid-induced memory deficiency
Bie, B., Wu, J., Yang, H., Xu, J. J., Brown, D. L., & Naguib, M. (2014) · Nature Neuroscience · doi:10.1038/nn.3618 · Cited by 112
Kimura, K., Ikoma, A., Shibakawa, M., Shimoda, S., Harada, K., Saio, M., Imamura, J., Osawa, Y., Kimura, M., Nishikawa, K., et al. (2017) · EBioMedicine · doi:10.1016/j.ebiom.2017.08.016 · Cited by 112
Structure-guided development of YEATS domain inhibitors by targeting π-π-π stacking
Li, X., Li, X.-M., Jiang, Y., Liu, Z., Cui, Y., Fung, K. Y., van der Beelen, S. H. E., Tian, G., Wan, L., Shi, X., et al. (2018) · Nature Chemical Biology · doi:10.1038/s41589-018-0144-y · Cited by 110
Self-citationSaikosaponin D exhibits anti-leukemic activity by targeting FTO/m6A signaling
Sun, K., Du, Y., Hou, Y., Zhao, M., Li, J., Du, Y., Zhang, L., Chen, C., Yang, H., Yan, F., et al. (2021) · Theranostics · doi:10.7150/thno.55574 · Cited by 110
Vieito, M., Moreno, V., Spreafico, A., Braña, I., Wang, J. S.-Z., Preis, M., Hernández‐Guerrero, T., Genta, S., Hansen, A. R., Doger, B., et al. (2023) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-23-0092 · Cited by 110
Targeting the acetylation signaling pathway in cancer therapy
Dang, F., & Wei, W. (2022) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2021.03.001 · Cited by 109
A patent review of arginine methyltransferase inhibitors (2010–2018)
Xiao, L., Wang, C., Jiang, H., & Luo, C. (2019) · Expert Opinion on Therapeutic Patents · doi:10.1080/13543776.2019.1567711 · Cited by 108
Xie, G., Wu, X.-N., Ling, Y., Rui, Y., Wu, D., Zhou, J., Li, J., Lin, S., Peng, Q., Li, Z., et al. (2021) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2021.08.028 · Cited by 108
Discovery of Norbornene as a Novel Hydrophobic Tag Applied in Protein Degradation
Xie, S., Zhan, F., Zhu, J., Sun, Y., Zhu, H., Liu, J., Chen, J., Zhu, Z., Yang, D., Chen, Z., et al. (2023) · Angewandte Chemie International Edition · doi:10.1002/anie.202217246 · Cited by 108
Pauer, L. R., Olivares, J., Cunningham, C., Williams, A., Grove, W., Kraker, A., Olson, S., & Nemunaitis, J. (2004) · Cancer Investigation · doi:10.1081/cnv-200039852 · Cited by 107
Cited by
Age reprogramming: Innovations and ethical considerations for prolonged longevity (Review)
Saliev, T., & Singh, P. (2025) · Biomedical Reports · doi:10.3892/br.2025.1974 · Cited by 14
Metadata
- Authors
- Dai, W., Qiao, X., Fang, Y., Guo, R., Bai, P., Liu, S., Li, T., Jiang, Y., Wei, S., Na, Z., Xiao, X., & Li, D.
- Venue
- Signal Transduction and Targeted Therapy
- Published
- 2024-11-26
- Volume
- 9
- Issue
- 1
- Pages
- 332-332
- ISSN
- 2059-3635 (ISSN-L)
- OpenAlex
- W4404726166
- Cited by
- 339
- References
- 1,077
- FWCI
- 39.39
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.